New-Generation Heterocyclic Bis-Pentamethinium Salts as Potential Cytostatic Drugs with Dual IL-6R and Mitochondria-Targeting Activity

Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Ekonomicko-správní fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

TALIANOVÁ Veronika KEJÍK Zdeněk KAPLÁNEK Robert VESELÁ Kateřina ABRAMENKO Nikita LACINA Lukáš STRNADOVÁ Karolína DVOŘÁNKOVÁ Barbora MARTÁSEK Pavel MASAŘÍK Michal MEGOVÁ HOUDOVÁ Magdalena BUŠEK Petr KŘÍŽOVÁ Jana ZDRAŽILOVÁ Lucie HANSÍKOVÁ Hana VLČÁK Erik FILIMONENKO Vlada ŠEDO Aleksi SMETANA JR. Karel JAKUBEK Milan

Rok publikování 2022
Druh Článek v odborném periodiku
Časopis / Zdroj Pharmaceutics
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.mdpi.com/1999-4923/14/8/1712
Doi http://dx.doi.org/10.3390/pharmaceutics14081712
Klíčová slova IL-6R synthetic inhibitors; mitochondria; cancer
Přiložené soubory
Popis IL-6 signaling is involved in the pathogenesis of a number of serious diseases, including chronic inflammation and cancer. Targeting of IL-6 receptor (IL-6R) by small molecules is therefore an intensively studied strategy in cancer treatment. We describe the design, synthesis, and characteristics of two new bis-pentamethinium salts 5 and 6 (meta and para) bearing indole moieties. Molecular docking studies showed that both compounds have the potential to bind IL-6R (free energy of binding -9.5 and -8.1 kcal/mol). The interaction with IL-6R was confirmed using microscale thermophoresis analyses, which revealed that both compounds had strong affinity for the IL-6R (experimentally determined dissociation constants 26.5 ± 2.5 nM and 304 ± 27.6 nM, respectively). In addition, both compounds were cytotoxic for a broad spectrum of cancer cell lines in micromolar concentrations, most likely due to their accumulation in mitochondria and inhibition of mitochondrial respiration. In summary, the structure motif of bis-pentamethinium salts represents a promising starting point for the design of novel multitargeting compounds with the potential to inhibit IL-6 signaling and simultaneously target mitochondrial metabolism in cancer cells.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.